-transparent.png){kind=logo}
In a large multicentre study of 429 patients with the usual signs and symptoms of non-specific vaginitis (NSV), we studied the effect of different doses of metronidazole. The patients were divided into five treatment groups as follows: group A was given 400 mg metronidazole three times daily for seven days, group B 2000 mg as a single dose, group C 2000 mg on days 1 and 2, group D 2000 mg on days 1 and 3, and group E was given 1200 mg metronidazole once daily for five days. At follow up examination four weeks from the start of treatment, patients in groups D and E showed the best clinical results with cure rates of 94.0% and 93.6% respectively. In addition the rate of reisolation of Gardnerella vaginalis was lowest in group D. We therefore recommend metronidazole 2000 mg on days 1 and 3 as routine treatment for non-specific or vaginitis associated with gardnerella.
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
April 1987,
Indian journal of pathology & microbiology,
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
January 1983,
Scandinavian journal of infectious diseases. Supplementum,
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
May 1980,
Lancet (London, England),
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
May 1980,
Lancet (London, England),
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
January 1983,
Scandinavian journal of infectious diseases. Supplementum,
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
January 1983,
Scandinavian journal of infectious diseases. Supplementum,
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
January 1990,
Vestnik dermatologii i venerologii,
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
August 1963,
The Journal of the Kansas Medical Society,
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
May 1985,
The New Zealand medical journal,
F Jerve, and
T B Berdal, and
P Bohman, and
C C Smith, and
O K Evjen, and
H Gjønnaess, and
M Gaasemyr, and
L Hausken, and
K Hesla, and
E Hoftvedt
June 1984,
Lancet (London, England),
